Warm hemolytic anemia is a rare condition that affects your red blood cells. It causes anemia-like symptoms, such as fatigue, jaundice, and paleness. Share on Pinterest ZeynepKaya/Getty Images In warm ...

"People living with warm autoimmune hemolytic anemia face a serious, life-threatening disease with no approved treatment options and a high risk of complications, including profound chronic fatigue, ...

Cold antibody hemolytic anemia is a rare autoimmune disorder characterized by the premature destruction of red blood cells by autoantibodies at temperatures of approximately 0 to 10 degrees Celsius. Q ...

Phase 2b LUMINA 2 study data support rilzabrutinib's FDA Breakthrough Therapy designation for the treatment of warm autoimmune hemolytic anemia. The Food and Drug Administration (FDA) has granted ...

Autoimmune hemolytic anemia (AIHA) and paroxysmal nocturnal hemoglobinuria (PNH) are distinct blood disorders with different underlying causes and treatment approaches. Each is rare and potentially ...

The FDA has approved Pyrukynd (mitapivat) for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency. The Food and Drug Administration (FDA) has approved Pyrukynd ® (mitapivat) ...

Mihir Raval, MD, MPH, comments on the difference between cold agglutinin disease and other autoimmune hemolytic anemias. Neil Minkoff, MD: Now, you had mentioned that there are other autoimmune ...

Additional population-based studies of autoimmune hemolytic anemia and its management are needed to reduce mortality in this patient population. Autoimmune hemolytic anemia (AIHA) is typically a ...

THE absence of anemia in infectious mononucleosis is generally accepted. Indeed, this fact is useful as an aid in the differential diagnosis of infectious mononucleosis and leukemia. Bernstein 1 has ...

The following report presents 3 cases of intravascular hemolysis that followed aortic-valve replacement with cusps composed of Dacron cloth impregnated with silicone rubber. 8,9 Hematologic data on 32 ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved mitapivat for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency.